Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Vera Hárs et al.|New England Journal of Medicine|2012Cited by 1.1k
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic MalignanciesMohamed L. Sorror, Rainer Storb, Brenda M. Sandmaier et al.|JAMA|2011Cited by 320
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell TransplantationRainer Storb, Brenda M. Sandmaier, Boglarka Gyurkocza et al.|Journal of Clinical Oncology|2013Cited by 212
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Vikas Gupta, Uday Popat et al.|Biology of Blood and Marrow Transplantation|2015Cited by 142
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Arnaud Jaccard, Chris Venner, Raymond L. Comenzo et al.|Haematologica|2014Cited by 129